Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing. The investors included IMM Investment, KDB Investment and Atinum.
Source: Press Release
Orum Therapeutics rakes in $84m Series B
Orum Therapeutics, a developer of targeted protein degraders to treat cancer, has raised $84 million in Series B financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: